ArriVent BioPharma, Inc. SEC filings

Filings

1. SCHEDULE 13GArriVent BioPharma, Inc.AVBP5d

   ArriVent BioPharma, Inc. 13G filing by Vivo Opportunity Fund

   • Vivo Opportunity Fund Holdings, L.P. owns 3.1% of ArriVent BioPharma
   • Vivo Opportunity, LLC owns 5.0% of ArriVent BioPharma
   • Total shares beneficially owned by all entities: 4,991,344

   Vivo Opportunity Fund Holdings, L.P., filed by

2. 8-KArriVent BioPharma, Inc.AVBP6d

   ArriVent BioPharma doses first patient in Phase 1 trial

   • October 12, 2026 - First patient dosed with ARR-002
   • ARR-002 is a dual-target tetravalent ADC for ovarian and endometrial cancer
   • Phase 1 trial (NCT07755436) evaluates safety and efficacy
3. SCHEDULE 13D/AArriVent BioPharma, Inc.AVBPOct 8

   ArriVent BioPharma, Inc. reports ownership changes.

   • OrbiMed Advisors LLC holds 2,875,962 shares (5.8%)
   • OrbiMed Capital GP VIII LLC holds 1,437,981 shares (2.9%)
   • OrbiMed Asia GP IV, L.P. holds 1,437,981 shares (2.9%)

   ORBIMED ADVISORS LLC, filed by

4. 8-KArriVent BioPharma, Inc.AVBPOct 6

   ArriVent BioPharma misses trial goal

   • Phase 3 FURVENT trial did not meet PFS primary endpoint
   • 240mg firmonertinib showed 11.0 months PFS vs 9.5 months control
   • Safety profile consistent with prior studies
5. 10-QArriVent BioPharma, Inc.AVBPAug 12

   Quarterly report

6. 8-KArriVent BioPharma, Inc.AVBPAug 12

   Current report

7. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPJul 27

   Ownership stake disclosure by BlackRock, Inc. (amended)

   BlackRock, Inc., filed by

8. 4ArriVent BioPharma, Inc.AVBPJun 22

   4 insider filings

   Merdad Parsey, insider filing for AVBP

   Show all 4

   • 4Insider filing for AVBPJun 22
   • 4Insider filing for AVBPJun 22
   • 4Insider filing for AVBPJun 22
   • 4Insider filing for AVBPJun 22

   Merdad Parsey, reporting

9. 8-KArriVent BioPharma, Inc.AVBPJun 22

   Current report

10. 8-KArriVent BioPharma, Inc.AVBPMay 11

    Current report

11. 424B5ArriVent BioPharma, Inc.AVBPMay 11

    Securities offering

12. 8-KArriVent BioPharma, Inc.AVBPMay 11

    Current report

13. 10-QArriVent BioPharma, Inc.AVBPMay 11

    Quarterly report

14. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPMay 6

    Ownership stake disclosure by FMR LLC (amended)

    FMR LLC, filed by

15. ARSArriVent BioPharma, Inc.AVBPApr 28

    Annual report to shareholders

16. DEFA14AArriVent BioPharma, Inc.AVBPApr 28

    Additional proxy materials

17. DEF 14AArriVent BioPharma, Inc.AVBPApr 28

    Proxy statement

18. 8-KArriVent BioPharma, Inc.AVBPMar 17

    Current report

19. S-8ArriVent BioPharma, Inc.AVBPMar 5

    Employee stock plan registration

20. 10-KArriVent BioPharma, Inc.AVBPMar 5

    Annual report

21. 8-KArriVent BioPharma, Inc.AVBPMar 5

    Current report

22. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPMar 5

    Ownership stake disclosure by Sofinnova Venture Partners IX, L.P. (amended)

    Sofinnova Venture Partners IX, L.P., filed by

23. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPFeb 17

    Ownership stake disclosure by INFINITUM ASSET MANAGEMENT, LLC (amended)

    INFINITUM ASSET MANAGEMENT, LLC, filed by

24. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPFeb 17

    Ownership stake disclosure by HILLHOUSE INVESTMENT MANAGEMENT, LTD. (amended)

    HILLHOUSE INVESTMENT MANAGEMENT, LTD., filed by

25. 4ArriVent BioPharma, Inc.AVBPFeb 4

    5 insider filings

    Robin LaChapelle, insider filing for AVBP

    Show all 5

    • 4Insider filing for AVBPFeb 4
    • 4Insider filing for AVBPFeb 4
    • 4Insider filing for AVBPFeb 4
    • 4Insider filing for AVBPFeb 4
    • 4Insider filing for AVBPFeb 4

    Robin LaChapelle, reporting

26. 4ArriVent BioPharma, Inc.AVBPFeb 3

    HILLHOUSE INVESTMENT MANAGEMENT, LTD., insider filing for AVBP

    HILLHOUSE INVESTMENT MANAGEMENT, LTD., reporting · HHLR ADVISORS, LTD., reporting

27. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPJan 30

    Ownership stake disclosure by VANGUARD GROUP INC (amended)

    VANGUARD GROUP INC, filed by

28. SCHEDULE 13GArriVent BioPharma, Inc.AVBPJan 21

    Ownership stake disclosure by BlackRock, Inc.

    BlackRock, Inc., filed by

29. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPNov 14, 2025

    Ownership stake disclosure by Octagon Capital Advisors LP (amended)

    Octagon Capital Advisors LP, filed by

30. 10-QArriVent BioPharma, Inc.AVBPNov 10, 2025

    Quarterly report

31. 8-KArriVent BioPharma, Inc.AVBPNov 10, 2025

    Current report

32. SCHEDULE 13G/AArriVent BioPharma, Inc.AVBPNov 5, 2025

    Ownership stake disclosure by FMR LLC (amended)

    FMR LLC, filed by

33. SCHEDULE 13GArriVent BioPharma, Inc.AVBPOct 30, 2025

    Ownership stake disclosure by VANGUARD GROUP INC

    VANGUARD GROUP INC, filed by

Older filings on EDGAR